title: Ciclosporin use in dry eye disease patients.
abstract: BACKGROUND
  Dry eye disease is one of the most commonly encountered conditions in eye care, and inflammation is a frequent finding. Ciclosporin has long been used systemically to decrease the deleterious effects of inflammation. Ciclosporin is a calcineurin inhibitor that acts by primarily blocking the action of T cells, decreasing the release of pro-inflammatory cytokines, and preventing the apoptosis of goblet cells.
  
  
  OBJECTIVE
  This article reviews the clinical trials and safety profile of an ophthalmic preparation of ciclosporin in the treatment of dry eye.
  
  
  CONCLUSIONS
  Clinical trials have demonstrated that ciclosporin minimizes the signs and symptoms of dry eye disease and is not associated with any significant systemic or ocular adverse reaction.
authors.affiliation: Southern California College of Optometry, 2575 Yorba Linda Boulevard, Fullerton, CA 92831, USA. wridder@scco.edu
authors.forename: William H
authors.initials: WH
authors.lastname: Ridder
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004361:Drug Tolerance; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000473:pathology; D006801:Humans
chemical_list: D016572:Cyclosporine